Cell Biosciences Accelerates Transition to Commercial Entity, Plans to Buy Alpha Innotech for $20M

For a firm that launched its first product commercially only five months ago, the proposed deal represents a major move to grow its footprint. Just over a year ago, Cell Biosciences underwent a total reorganization in its management to segue from being a technology startup to a company focused on commercializing its products

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories